AUTHOR=Chen Chao , Zhang Wei , Zhou Daobin , Zhang Yan 

TITLE=Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review

JOURNAL=Frontiers in Oncology

VOLUME=Volume 11 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.757403

DOI=10.3389/fonc.2021.757403

ISSN=2234-943X

ABSTRACT=Relapsed/refractory (R/R) transformed diffused large B cell lymphoma (tDLBCL) has a poor prognosis, studies about new therapies for tDLBCL are scarce. PD-1 antibody and histone deacetylase inhibitor both have anti-lymphoma effects but the combination of these two therapies hasn’t been explored in DLBCL. Here, we present a successful combination therapy of sintilimab and chidamide for R/R tDLBCL. The patient was a 71-year-old man with pulmonary mucosa-associated lymphoid tissue lymphoma. He didn’t receive any treatment until transformed DLBCL was confirmed 2 years later. The tDLBCL was primary refractory to R2-CHOP, R2-MTX, and Gemox regimens. However, he achieved sustained complete remission after the combination therapy of sintilimab and chidamide. According to our knowledge, this is the first report of sintilimab combined with chidamide for treatment of R/R tDLBCL, which opens up new therapeutic possibilities of this new combination therapy in future prospective clinical trials.